

EXHIBIT 2

UNITED STATES DISTRICT COURT
MIDDLE DISTRICT OF FLORIDA
ORLANDO DIVISION

IN RE: Seroquel Products Liability
Litigation

MDL DOCKET NO. 1769

This Document Relates to 6:06-cv-1295

DEPOSITION OF FARRIS T. JOHNSON, JR., M.D.
Wednesday, September 26, 2007

610 Oglethorpe Avenue
Suite B
Athens, Georgia 30606

Reported By:
Judith L. Leitz, RPR
Georgia CCR-B-2312
Esquire Deposition Services
Atlanta Office Job No. 425003
Phone - 404-872-7890

Page 2

1 UNITED STATES DISTRICT COURT
 2 MIDDLE DISTRICT OF FLORIDA
 3 ORLANDO DIVISION
 4 IN RE: Seroquel Products Liability
 5 Litigation
 6 MDL DOCKET NO. 1769
 7 This Document Relates to 6:06-cv-1295

8
 9
 10 Deposition of FARRIS T. JOHNSON, M.D.,
 11 taken on behalf of the Defendant AstraZeneca,
 12 pursuant to the stipulations agreed to herein, before
 13 Judith L. Leitz, Certified Court Reporter, at 610
 14 Oglethorpe Avenue, Suite B, Athens, Georgia, on
 15 Wednesday, the 26th day of September, 2007,
 16 commencing at the hour of 2:22 p.m.
 17
 18
 19
 20
 21
 22
 23
 24
 25 Job No. 425003

Page 3

1 APPEARANCES OF COUNSEL
 2 On behalf of the Plaintiff:
 3 DEBRA DeCARLI, ESQUIRE
 4 LAURA M. BRANDENBERG, ESQUIRE
 5 Levin Simes Kaiser & Gornick, L.L.P.
 6 44 Montgomery Street
 7 36th Floor
 8 San Francisco, California 94104
 9 (415) 646-7160
 10 (415) 981-1270 fax
 11 e-mail: ddecarli@lskg-law.com
 12 lbrandenberg@lskg-law.com
 13
 14 On behalf of the Defendant AstraZeneca:
 15 LAURA LEWIS OWENS, ESQUIRE
 16 Alston & Bird, L.L.P.
 17 One Atlantic Center
 18 1201 West Peachtree Street
 19 Atlanta, Georgia 30309
 20 (404) 881-7000
 21 (404) 881-7777 fax
 22 e-mail: lowens@alston.com
 23
 24 ALSO PRESENT: Marshall Willis with Alston & Bird
 25

Page 4

1 INDEX
 2 WITNESS: FARRIS T. JOHNSON, M.D.
 3 EXAMINATION PAGE
 4 By Ms. Owens 6
 5 By Ms. DeCarli 82
 6 By Ms. Owens 120
 7 By Ms. DeCarli 135
 8
 9 EXHIBITS
 10 NO. DESCRIPTION PAGE
 11 1 Notice of Deposition 47
 12 2 05/29/01 to 06/2/01 Discharge Summary 47
 13 3 9/16/06 To Whom it May Concern letter 49
 14 4 6/16/00 History and Physical Examination; 49
 15 10/19/00 Discharge Summary; 5/26/01 History
 16 and Physical Examination
 17 5 3/9/04 Medical Record 56
 18 6 5/11/04 Medical Record 58
 19 7 8/23/04 Medical Record 58
 20 8 9/13/04 Medical Record 62
 21 9 10/25/04 Medical Record 64
 22 10 10/17/05 Medical Record 72
 23 11 12/1/05 Medical Record 76
 24 12 CV of Dr. Johnson 81
 25 13 4/12/05 Office Note 86
 14 14 Spreadsheet - Prescribing Record 87

Page 5

1 EXHIBITS (CONT.)
 2 NO. DESCRIPTION PAGE
 3 15 Draft - Voicemail Script 94
 4 16 Objection Handler on Atypical antipsychotics 95
 5 and glucose dysregulation
 6 17 AstraZeneca - Important Drug Information - 97
 7 January 30, 2004
 8 18 Final: February 3, 2004, Diabetes Master 99
 9 Question and Answer Document
 10 19 Article - June 2004 - A Survey of Reports of 101
 11 Quetiapine-Associated Hyperglycemia and
 12 Diabetes Mellitus
 13 20 Article - September 2004 - Relationship 103
 14 Between Antipsychotic Medication Treatment
 15 and New Cases
 16 of Diabetes Among Psychiatric Inpatients
 17 21 Article 2006 - American Journal of 104
 18 Epidemiology - Diabetes Risk Associated with
 19 Use of Olanzapine, Quetiapine, and Risperidone
 20 in Veterans Health Administration Patients with
 21 Schizophrenia
 22 22 AstraZeneca - What you need to know to Detail 107
 23 the PCP Mania Self Sheet for Seroquel
 24 23 Spreadsheet - Call Notes 109
 25 24 Group exhibit - Medical Records 138

Page 118

1 uncommon and certainly have to be interpreted in the
 2 context of the patient. Most patients with
 3 extrapyramidal side effects, EPS, interestingly
 4 enough don't complain of tremors. They have other
 5 complaints, but tremors in my experience is not a
 6 predominant complaint associated with that medication
 7 by the patient.
 8 Q. To your knowledge, has Ms. Thomas ever been
 9 tested for EPS?
 10 A. There is not a formal test for it. It's
 11 more of a -- it's confirmed by physical diagnosis. I
 12 would say this, she's seen enough people familiar
 13 with EPS that if that had been a predominant problem,
 14 I would have expected psychiatrists and neurologists
 15 to pick that up pretty easily.
 16 Q. Given the drugs that she was on?
 17 A. Correct.
 18 Q. Okay.
 19 A. It's the kind of thing that you -- you
 20 observe patients who are being treated with
 21 psychiatric medications and I don't think it would
 22 have gone unnoticed by the number of people that she
 23 had seen, I don't think.
 24 Q. Dr. Johnson, is it a fair summary of your
 25 testimony that adequate warnings from AstraZeneca

Page 119

1 regarding diabetes risks would have altered your
 2 prescribing recommendations for Ms. Thomas?
 3 A. Yes.
 4 MS. DeCARLI: I am going to pass the
 5 witness, but I am leaving the deposition open in
 6 light of the fact that just 38 hours before the
 7 beginning of this deposition we received a
 8 significant amount of new records. AstraZeneca's
 9 first disclosure was on August 3rd and they waited
 10 until September 24th at midnight to disclose records.
 11 So, unfortunately, Dr. Johnson, we may have to
 12 continue on another day, but I am reserving the right
 13 to reopen.
 14 MS. OWENS: And I recognize that the time
 15 was close, but would note that the obligation was to
 16 provide it before the deposition and you will agree
 17 that it was received before this deposition, correct?
 18 MS. DeCARLI: I will agree that it was
 19 received nine hours before I met with the Plaintiff
 20 to present her for her deposition and we were with
 21 the Plaintiffs from 9:00 a.m. yesterday morning,
 22 didn't start the deposition until 40 minutes late,
 23 and didn't finish until 6:30 last evening, which did
 24 not leave very much time for preparation and I don't
 25 think it's very reasonable on the part of AstraZeneca

Page 120

1 to expect that that was proper notice. So we reserve
 2 our right to continue based upon the late received
 3 records.
 4 FURTHER EXAMINATION
 5 BY MS. OWENS:
 6 Q. Doctor, you talked earlier about your
 7 discussions you would have in your considerations of
 8 risks and benefits of medications you prescribe to
 9 your patients, correct?
 10 A. Correct.
 11 Q. So I assume to the extent that there are
 12 warnings about particular drugs made by the FDA or on
 13 the product labeling that you found significant those
 14 would be warnings you would also discuss with your
 15 patients, correct?
 16 A. Yes.
 17 Q. And that would be true as -- not just as to
 18 all medications but as to Seroquel specifically?
 19 A. Known to me at that time, yes.
 20 Q. Now, some information was provided to you
 21 that Ms. Thomas may have been receiving Seroquel
 22 samples from someone other than you in 2004, correct?
 23 A. Today, yes.
 24 Q. And do you have any record of prescribing
 25 Seroquel for her in 2004?

Page 121

1 A. No.
 2 Q. So to the extent the records you reviewed
 3 during Plaintiff's counsel's cross-examination or
 4 examination of you showed numbers of patients
 5 receiving prescriptions from you for Seroquel that
 6 would not have included Hellen Thomas as best you can
 7 tell from your records today?
 8 A. Correct.
 9 Q. And does the information that this patient
 10 may have been obtaining samples from her psychiatrist
 11 or from Advantage during 2004 change your opinion
 12 that you offered earlier that Seroquel was not the
 13 cause of Ms. Thomas's diabetes?
 14 A. Say that again.
 15 Q. Does the information that Ms. Thomas may
 16 have been receiving Seroquel samples in 2004 from her
 17 psychiatrist or from Advantage healthcare
 18 professionals change the opinion you offered earlier
 19 that Seroquel was not the cause of Ms. Thomas's
 20 diabetes?
 21 A. No.
 22 Q. And I believe you said that in your
 23 experience it has not been the case that Seroquel has
 24 caused diabetes in your patients?
 25 A. Correct.